Inhibitory effect of soluble platelet-derived growth factor receptor β on intraosseous growth of breast cancer cells in nude mice

Cancer Science

Volumn 102, Issue 10, 2011, Pages 1904-1910

  Shan, Hongchao ^a   Takahashi, Tetsuyuki ^a   Bando, Yoshimi ^b   Izumi, Keisuke ^a   Uehara, Hisanori ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR D; PROGESTERONE RECEPTOR; RECOMBINANT PLATELET DERIVED GROWTH FACTOR BB;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ATTENUATION; BONE MARROW CELL; BONE METASTASIS; CANCER CELL; CANCER GROWTH; CANCER INCIDENCE; CANCER INHIBITION; CELL PROLIFERATION; CELL THERAPY; CONTROLLED STUDY; EXPRESSION VECTOR; FIBROBLAST; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STROMA CELL; TRIPLE NEGATIVE BREAST CANCER;

ANIMALS; APOPTOSIS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE TRANSFER TECHNIQUES; HUMANS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PLATELET-DERIVED GROWTH FACTOR; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; SOLUBILITY; STROMAL CELLS;

EID: 80053383766     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02026.x     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2007; 57: 43-66.
2. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987; 55: 61-6.
3. Chirgwin JM, Guise TA. Skeletal metastases: decreasing tumor burden by targeting the bone microenvironment. J Cell Biochem 2007; 102: 1333-42.
4. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27: 165-76.
5. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 2007; 109: 1721-8.
6. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-81.
7. Kang Y, Siegel PM, Shu W et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3: 537-49.
8. Canalis E, Varghese S, McCarthy TL, Centrella M. Role of platelet derived growth factor in bone cell function. Growth Regul 1992; 2: 151-5.
9. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008; 22: 1276-312.
10. Ustach CV, Huang W, Conley-LaComb MK et al. A novel signaling axis of matriptase/PDGF-D/b-PDGFR in human prostate cancer. Cancer Res 2010; 70: 9631-40.
11. Cao R, Björndahl MA, Religa P et al. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 2004; 6: 333-45.
12. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999; 79: 1283-316.
13. Rönnstrand L, Heldin CH. Mechanisms of plateletderived growth factor-induced chemotaxis. Int J Cancer 2001; 91: 757-62.
14. Tallquist M, Kazlauskas A. PDGF signaling in cells and mice. Cytokine Growth Factor Rev 2004; 15: 205-13.
15. Carvalho I, Milanezi F, Martins A, Reis RM, Schmitt F. Overexpression of platelet-derived growth factor receptor α in breast cancer is associated with tumour progression. Breast Cancer Res 2005; 7: 788-95.
16. Ariad S, Seymour L, Bezwoda WR. Platelet-derived growth factor (PDGF) in plasma of breast cancer patients: correlation with stage and rate of progression. Breast Cancer Res Treat 1991; 20: 11-7.
17. Ustach CV, Taube ME, Hurst NJ Jr et al. A potential oncogenic activity of platelet-derived growth factor d in prostate cancer progression. Cancer Res 2004; 64: 1722-79.
18. Ustach CV, Kim HR. Platelet-derived growth factor D is Activated by urokinase plasminogen activator in prostate carcinoma cells. Mol Cell Biol 2005; 25: 6279-88.
19. Kong D, Wang Z, Sarkar SH et al. Platelet-derived growth factor-D overexpression contributes to epithelial mesenchymal transition of PC3 prostate cancer cells. Stem Cells 2008; 26: 1425-35.
20. Wang Z, Kong D, Banerjee S et al. Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and nuclear factor-κB signaling. Cancer Res 2007; 67: 11377-85.
21. Xu L, Tong R, Cochran DM, Jain RK. Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor-β signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer Res 2005; 65: 5711-9.
22. Bertino P, Piccardi F, Porta C et al. Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts. Clin Cancer Res 2008; 14: 541-8.
23. Donnem T, Al-Saad S, Al-Shibli K, Busund LT, Bremnes RM. Co-expression of PDGFB and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small cell lung cancer. Ann Oncol 2010; 21: 223-31.
24. Gehmert S, Gehmert S, Prantl L, Vykoukal J, Alt E, Song YH. Breast cancer cells attract the migration of adipose tissue-derived stem cells via the PDGF-BB/PDGFR-β signalin g pathway. Biochem Biophys Res Commun 2010; 398: 601-5.
25. Jechlinger M, Sommer A, Moriggl R et al. Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest 2006; 116: 1561-70.
26. Cimpean AM, Raica M. Platelet-derived growth factor (PDGF)/PDGF receptors (PDGFR) axis as target for antitumor and antiangiogenic therapy. Pharmaceuticals 2010; 3: 572-99.
27. Paulsson J, Sjoblom T, Micke P et al. Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol 2009; 175: 334-41.
28. Hermanson M, Funa K, Hartman M et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 1992; 52: 3213-9.
29. Guo P, Hu B, Gu W et al. Platelet derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth actor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol 2003; 162: 1083-93.
30. Ahmad A, Wang Z, Kong D et al. Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-κB signaling pathways. Breast Cancer Res Treat 2011; 126: 15-25.
31. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004; 432: 332-7.
32. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999; 59: 5002-11.
33. Yoneda T, Sasaki A, Mundy GR. Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat 1994; 32: 73-84.
34. Baylink DJ, Finkelman RD, Mohan S. Growth factors to stimulate bone formation. J Bone Miner Res 1993; 8(Suppl 2): 565-72.
35. Bruna A, Darken RS, Rojo F et al. High TGFβ-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 2007; 11: 147-60.
36. Uehara H, Kim SJ, Karashima T et al. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastasis. J Natl Cancer Inst 2003; 95: 558-70.
37. Cristofanilli M, Morandi P, Krishnamurthy S et al. Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-kit or PDGFR-β: clinical activity and biological correlations. Ann Oncol 2008; 19: 1713-9.
38. Lokker NA, O'Hare JP, Barsoumian A et al. Functional importance of platelet-derived growth factor (PDGF) receptor extracellular immunoglobulin-like domains. J Biol Chem 1997; 272: 33037-44.
39. Takahashi T, Uehara H, Bando Y, Izumi K. Soluble EP2 neutralize prostaglandin E2-induced cell signaling and inhibits osteolytic tumor growth. Mol Cancer Ther 2008; 7: 2807-16.
40. Furuhashi M, Sjölom T, Abramsson A et al. Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. Cancer Res 2004; 64: 2725-33.
41. Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kB-dependent manner. Cancer Cell 2010; 17: 135-47.
42. Nannuru KC, Singh RK. Tumor-stromal interactions in bone metastasis. Curr Osteoporos Rep 2010; 8: 105-13.
43. Bussard KM, Gay CV, Mastro AM. The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis Rev 2008; 27: 41-55.
44. Suva LJ, Griffin RJ, Makhoul I. Mechanisms of bone metastases of breast cancer. Endocr Relat Cancer 2009; 16: 703-13.
45. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350: 1655-64.
46. Balabanov S, Appel S, Kanz L, Brossart P, Brümmendorf TH. Effect of tyrosine kinase inhibition using Imatinib on normal lymphohematopoietic cells. Ann NY Acad Sci 2005; 1044: 168-77.
47. Song S, Ewald AJ, Stallcup W, Werb Z, Bergers G. PDGFRβ+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 2005; 7: 870-9.
48. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 111: 1287-95.
49. Skobe M, Fusenig NE. Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. Proc Natl Acad Sci USA 1998; 95: 1050-5.